Scandinavian ChemoTech AB Class B (8V6) Stock Statistics & Valuation Metrics
Total Valuation
Scandinavian ChemoTech AB Class B has a market cap or net worth of EUR 4.91M. The enterprise value is EUR 95.90M.
- Market Cap
- EUR 4.91M
- Enterprise Value
- EUR 95.90M
Share Statistics
Scandinavian ChemoTech AB Class B has 23,802,313 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,802,313
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Scandinavian ChemoTech AB Class B’s return on equity (ROE) is -2.53 and return on invested capital (ROIC) is -197.80%.
- Return on Equity (ROE)
- -2.53
- Return on Assets (ROA)
- -0.61
- Return on Invested Capital (ROIC)
- -197.80%
- Return on Capital Employed (ROCE)
- -1.98
- Revenue Per Employee
- 12.29M
- Profits Per Employee
- -8.06M
- Employee Count
- 1
- Asset Turnover
- 0.93
- Inventory Turnover
- 6.01
Valuation Ratios
The current PE Ratio of Scandinavian ChemoTech AB Class B is -14.45. Scandinavian ChemoTech AB Class B’s PEG ratio is -0.13.
- PE Ratio
- -14.45
- PS Ratio
- 6.93
- PB Ratio
- 57.07
- Price to FCF
- -23.12
- Price to Operating Cash Flow
- -25.60
- PEG Ratio
- -0.13
Income Statement
In the last 12 months, Scandinavian ChemoTech AB Class B had revenue of 12.29M and earned -8.06M in profits. Earnings per share was -0.34.
- Revenue
- 12.29M
- Gross Profit
- -4.50M
- Operating Income
- -6.30M
- Pretax Income
- -8.06M
- Net Income
- -8.06M
- EBITDA
- -4.33M
- Earnings Per Share (EPS)
- -0.34
Cash Flow
In the last 12 months, operating cash flow was -3.65M and capital expenditures -130,000, giving a free cash flow of -3.78M billion.
- Operating Cash Flow
- -3.65M
- Free Cash Flow
- -3.78M
- Free Cash Flow per Share
- -0.15
Dividends & Yields
Scandinavian ChemoTech AB Class B pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.56%
- Earnings Yield
- -6.86%
Stock Price Statistics
- Beta
- -1.39
- 52-Week Price Change
- -64.10%
- 50-Day Moving Average
- 0.19
- 200-Day Moving Average
- 0.26
- Relative Strength Index (RSI)
- 44.18
- Average Volume (3m)
- 15.37K
Important Dates
Scandinavian ChemoTech AB Class B upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Feb 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Scandinavian ChemoTech AB Class B as a current ratio of 0.91, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.91
- Quick Ratio
- 0.63
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.85
- Interest Coverage Ratio
- -3.24
Taxes
In the past 12 months, Scandinavian ChemoTech AB Class B has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Scandinavian ChemoTech AB Class B EV to EBITDA ratio is -25.86, with an EV/FCF ratio of -21.58.
- EV to Sales
- 6.70
- EV to EBITDA
- -25.86
- EV to Free Cash Flow
- -21.58
- EV to Operating Cash Flow
- -21.58
Balance Sheet
Scandinavian ChemoTech AB Class B has EUR 1.46M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 1.46M billion.
- Cash & Marketable Securities
- EUR 1.46M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 1.46M
- Net Cash Per Share
- EUR 0.06
- Tangible Book Value Per Share
- -EUR 0.07
Margins
Gross margin is 52.64%, with operating margin of -41.65%, and net profit margin of -50.01%.
- Gross Margin
- 52.64%
- Operating Margin
- -41.65%
- Pretax Margin
- -50.01%
- Net Profit Margin
- -50.01%
- EBITDA Margin
- -25.91%
- EBIT Margin
- -41.65%
Analyst Forecast
The average price target for Scandinavian ChemoTech AB Class B is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 6.01%
- EPS Growth Forecast
- 13.03%
